ArticleBritish journal of clinical pharmacology2022
Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers.
Article in British journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07092215 (Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model - A Double-blind, Randomized, Placebo-controlled Crossover Study), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model - A Double-blind, Randomized, Placebo-controlled Crossover Study
Who cites it
16 citing papers in PubMed.
- RAGE mediates LPS-induced inflammatory pain in human skin - a double-blind, randomised, placebo-controlled full crossover study.Nature communications · 2026Trial
- Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone's impact on TLR4-mediated inflammation.Frontiers in immunology · 2026Trial
- Profiling a Neo-Antigen-Driven Immune Response in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Study of the KLH Challenge Model.Clinical pharmacology and therapeutics · 2025Trial
- POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses followingFrontiers in immunology · 2025Trial
- Open-Label Interventional Study in Healthy Volunteers to Evaluate NO-Mediated Vasodilation by Dermal Allyl Isothiocyanate Challenge and Whole-Body Heat Stress.Journal of experimental pharmacology · 2024Trial
- Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model.Frontiers in immunology · 2023Trial
- Clinical Validation of Imaging Biomarkers in Mycosis Fungoides.Experimental dermatology · 2026Article
- Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers.Clinical pharmacology and therapeutics · 2026Article
- Extending the IMQ Model: Deep Characterization of the Human TLR7 Response for Early Drug Development.Inflammation · 2025Article
- Neoantigen immune responses in healthy volunteers: insights from multiple integrated keyhole limpet hemocyanin challenge studies on repeated immunization and response covariates.Frontiers in pharmacology · 2025Article
- Glucocorticoids Do Not Affect the Vascular Component of TRP-Mediated Neurogenic Skin Inflammation.Journal of inflammation research · 2024Article
- The translational potential of inflammation-induced skin blister human models in exploring the pathogenesis of periodontitis and its systemic health implications.Frontiers in immunology · 2024Review
- Intradermal substance P as a challenge agent in healthy individuals.Clinical and translational science · 2023Article
- Inflammation Regulation by Bacterial Molecular Patterns.Biomedicines · 2023Article
- Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers.Clinical pharmacology and therapeutics · 2022Article
- Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers.British journal of clinical pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWhereas intravenous administration of Toll-like receptor 4 ligand lipopolysaccharide (LPS) to human volunteers is frequently used in clinical pharmacology studies, systemic use of LPS has practical limitations. We aimed to characterize the intradermal LPS response in healthy volunteers, and as such qualify the method as local inflammation model for clinical pharmacology studies.
methodsEighteen healthy male volunteers received 2 or 4 intradermal 5 ng LPS injections and 1 saline injection on the forearms. The LPS response was evaluated by noninvasive (perfusion, skin temperature and erythema) and invasive assessments (cellular and cytokine responses) in skin biopsy and blister exudate.
resultsLPS elicited a visible response and returned to baseline at 48 hours. Erythema, perfusion and temperature were statistically significant (P < .0001) over a 24-hour time course compared to saline. The protein response was dominated by an acute interleukin (IL)-6, IL-8 and tumour necrosis factor response followed by IL-1β, IL-10 and interferon-γ. The cellular response consisted of an acute neutrophil influx followed by different monocyte subsets and dendritic cells. DISCUSSION: Intradermal LPS administration in humans causes an acute, localized and transient inflammatory reaction that is well-tolerated by healthy volunteers. This may be a valuable inflammation model for evaluating the pharmacological activity of anti-inflammatory investigational compounds in proof of pharmacology studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.